{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:06:27Z","timestamp":1788278787085,"version":"build-2803163510"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) are the gold standard therapy for cutaneous melanoma and are also used effectively in treating other types of skin cancer. Hematologic toxicities are rare, but potentially a serious and life-threatening side effect of ICIs. Clinical and biological biomarkers able to predict these events have been poorly explored and have not yet been identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We present four cases of hematologic toxicity in melanoma patients and one case in a patient with cutaneous squamous cell carcinoma, all of which arose during treatment with ICIs in an adjuvant or metastatic setting. Hemolytic anemia was the most frequent event; neutropenia with agranulocytosis happened in one case and was fatal. ICI treatment was discontinued in all five cases and was never restarted. Two prevalent features were male sex and older age (&amp;gt;70\u00a0years old). These events were independent of the response to ICIs. Indeed, they occurred in a patient who progressed during treatment and in patients who responded completely to therapy. Previous diarrhea due to ICIs (patients 1, 2, and 5), asthenia (patients 3 and 4), and a sudden increase in lactate dehydrogenase levels despite the absence of disease progression (patients 2, 3, 4, and 5) might be warning signs of subsequent hematologic irAEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study underscores the rarity and potential severity of hematologic toxicities, underlining the need for heightened clinician awareness and the incorporation of hematologic guidance into oncologic practice. Although predictive biomarkers remain unvalidated, monitoring immune cell subsets or recognizing warning signals early on may facilitate diagnosis and improve prognosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1717727","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T06:44:14Z","timestamp":1767681854000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series"],"prefix":"10.3389","volume":"16","author":[{"given":"Rosa","family":"Falcone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Frezzolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Bruni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Verkhovskaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luigia","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Romana","family":"Di Pietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Chesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Piesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Cantonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"De Galitiis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Maria","family":"Failla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1186\/s12885-025-14733-5","article-title":"Adverse drug events of immune checkpoint inhibitors - a retrospective, descriptive real-world data analysis","volume":"25","author":"Auch","year":"2025","journal-title":"BMC Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1182\/blood.2022019024","article-title":"How I treat warm autoimmune hemolytic anemia","volume":"137","author":"Barcellini","year":"2023","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"392","DOI":"10.6004\/jadpro.2021.12.4.4","article-title":"Management of hematologic adverse events associated with immune checkpoint inhibitors","volume":"12","author":"Barnes","year":"2021","journal-title":"J. Adv. Pract. Oncol."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071819","article-title":"Sex and gender disparities in melanoma","volume":"12","author":"Bellenghi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06763-y","article-title":"Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: Meta-analysis of a rare immune-related adverse side effect","volume":"20","author":"Boegeholz","year":"2020","journal-title":"BMC Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1197630","DOI":"10.3389\/fimmu.2023.1197630","article-title":"Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy","volume":"14","author":"Carbone","year":"2023","journal-title":"Front. Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11912-020-0897-9","article-title":"Immune-related adverse events (irAEs): diagnosis, management, and clinical pearls","volume":"22","author":"Darnell","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"B7","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1634\/theoncologist.2018-0574","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"24","author":"Davis","year":"2019","journal-title":"Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","article-title":"Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study","volume":"6","author":"Delanoy","year":"2019","journal-title":"Lancet Haematol."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-023-00256-1","article-title":"A retrospective study of cemiplimab effectiveness in elderly patients with squamous cell carcinoma of the skin: insights from a Real-Life Scenario","volume":"12","author":"Di Lorenzo","year":"2024","journal-title":"Oncol. ther."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13249","article-title":"Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities","volume":"318","author":"Goodman","year":"2023","journal-title":"Immunol. Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann. Oncol."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3858","article-title":"Biomarkers for immunotherapy toxicity: Are cytokines the answer?","volume":"25","author":"Johnson","year":"2019","journal-title":"Cancer Res."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1447021","article-title":"Toxicity in the era of immune checkpoint inhibitor therapy","volume":"15","author":"Keam","year":"2024","journal-title":"Front Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ejca.2021.01.013","article-title":"Hematological immune related adverse events after treatment with immune checkpoint inhibitors","volume":"147","author":"Kramer","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1182\/blood.2020009016","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"139","author":"Kroll","year":"2022","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2795","article-title":"Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1\u2013based immunotherapy","volume":"25","author":"Lim","year":"2019","journal-title":"Cancer Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejca.2019.07.014","article-title":"Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?","volume":"122","author":"Michot","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01354","article-title":"Diagnosis and Management of Hematological Adverse Events Induced by Immune Checkpoint Inhibitors: A Systematic Review","volume":"11","author":"Omar","year":"2020","journal-title":"Front. Immunol."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219862341","article-title":"Immunotherapy-induced severe neutropenia with neurotoxicity: A case of a 75-year-old woman with ulcerative colitis diagnosed with melanoma","volume":"26","author":"Patel","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B13","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1159\/000447508","article-title":"Development of hemolytic anemia in a nivolumab-treated patient with refractory metastatic squamous cell skin cancer and chronic lymphatic leukemia","volume":"9","author":"Schwab","year":"2016","journal-title":"Case Rep. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00262-022-03230-4","article-title":"Hematologic malignancies following immune checkpoint inhibition for solid tumors","volume":"72","author":"van Eijs","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e011682","DOI":"10.1136\/jitc-2025-011682","article-title":"Circulating immunoregulatory B cell and autoreactive antibody profiles predict lack of toxicity to anti-PD-1 checkpoint inhibitor treatment in advanced melanoma","volume":"13","author":"Willsmore","year":"2025","journal-title":"J. Immunother. Cancer"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1717727\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T06:44:17Z","timestamp":1767681857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1717727\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":24,"alternative-id":["10.3389\/fphar.2025.1717727"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1717727","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"article-number":"1717727"}}